Last updated: February 24, 2026
What is the Drug Associated with NDC 11534-0190?
NDC 11534-0190 refers to Epinephrine Auto-Injector (0.3 mg), commonly marketed under brand names like EpiPen. It is a pre-filled device used for emergency treatment of anaphylaxis.
Current Market Landscape
Market Size and Demand
- The US epinephrine auto-injector market was valued at approximately $750 million in 2022.
- The growing prevalence of allergies and anaphylaxis cases drives demand.
- The FDA estimates about 2 million EpiPen prescriptions annually in the US alone.
Key Players
- Mylan (now part of Viatris) dominates, holding approximately 90% of the US market.
- Pfizer’s (Anapen) and Teva’s (Adrenaclick) occupy smaller market shares.
- Patent expirations and device approvals influence competitive dynamics.
Regulatory Environment
- FDA approval status remains stable for existing auto-injectors.
- Recent approvals include generic versions, increasing market competition.
- Pricing and access initiatives, such as the Trump-era rules, have aimed to lower costs but face implementation hurdles.
Price Trends and Projections
Historical Pricing Data
- 2010-2015: Average retail price for a dual pack ranged from $100 to $200.
- 2016-2019: Significant price hikes, reaching an average of $600 per pack.
- 2020-2022: Prices stabilized somewhat, averaging around $300 to $400 after increased competition and generic approval.
Factors Influencing Future Prices
- Introduction of generic epinephrine auto-injectors.
- Patent expirations and FDA approvals for alternative devices.
- Legislative efforts to cap prices or mandate manufacturer price disclosures.
- Supply chain disruptions, notably during the COVID-19 pandemic, causing temporary price volatility.
Price Projection (2023-2027)
| Year |
Estimated Average Price for a Dual Pack |
Notes |
| 2023 |
$300 - $350 |
Slight decline due to generics, increased competition |
| 2024 |
$250 - $300 |
Continued generic market penetration |
| 2025 |
$200 - $250 |
Expected regulatory pressures on pricing |
| 2026 |
$180 - $220 |
Market stabilization with multiple generics |
| 2027 |
$150 - $200 |
Potential further price reductions with new entrants |
Competitive Dynamics
- Generic versions, such as those from Teva, face price points below $100.
- Brand-name EpiPens maintain premiums up to $600 - $700 in some cases, although insurers often negotiate discounts.
- No large scale new device innovations are announced, limiting upward price pressure.
Strategic Considerations
- Companies controlling patent rights or exclusive distribution can maintain higher prices.
- Market entry barriers remain high due to regulatory approval times and production costs.
- Expanding access in emerging markets could influence global pricing but remains limited by local regulatory and reimbursement factors.
Summary
The epinephrine auto-injector market, centered on NDC 11534-0190, shows a trend toward decreasing retail prices driven by generic competition and regulatory pressures. The price is projected to decline gradually over the next five years, with a potential stabilization at around $150 to $200 for a dual pack.
Key Takeaways
- The US market is dominated by generics, which are priced significantly lower than branded devices.
- Patent expirations and new generic approvals will continue to pressure prices downward.
- Price stabilization around $150 to $200 can be expected by 2027.
- Insurers and healthcare providers influence actual patient costs through negotiation and formulary placement.
- Competitive pressure will limit brand-name pricing approaches unless device innovations or patent protections revive premium pricing.
FAQs
Q1: How do patent expirations impact EpiPen pricing?
A: Patents lasting roughly 10-12 years prevent generic competition, allowing brand-name devices to set higher prices. Once expired, generics enter the market at lower prices, pushing down overall costs.
Q2: Are there upcoming regulatory changes that could affect prices?
A: Yes. Recent proposals aim to cap out-of-pocket costs and improve transparency; these could reduce price variation but depend on legislative approval.
Q3: What is the impact of generic entry on the market?
A: Generics typically enter at 70-80% of brand prices, increasing competition and driving overall market prices downward.
Q4: How does healthcare reimbursement influence the retail price?
A: Reimbursement negotiations with insurers often lead to discounts, making actual patient costs lower than retail prices, especially when large pharmacy benefit managers are involved.
Q5: Will device innovations affect future pricing?
A: Significant new features or delivery methods could justify higher prices; however, current technological developments focus on manufacturing efficiencies rather than product differentiation.
References
[1] IBISWorld. (2022). U.S. Epinephrine Auto-Injectors Industry Report.
[2] IQVIA. (2022). US Prescription Data for Epinephrine Auto-Injectors.
[3] FDA. (2022). List of Approved Generic Drug Products.
[4] US Food and Drug Administration. (2021). Regulatory guidance on auto-injectors.
